180 Life Sciences Corp (ATNF)
1.68
-0.07
(-4.00%)
USD |
NASDAQ |
Sep 27, 16:00
1.71
+0.03
(+1.79%)
After-Hours: 20:00
180 Life Sciences SG&A Expense (Annual): 10.69M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.69M |
| December 31, 2022 | 15.47M |
| December 31, 2021 | 11.69M |
| Date | Value |
|---|---|
| December 31, 2020 | 3.355M |
| December 31, 2019 | 18.85M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.355M
Minimum
2020
18.85M
Maximum
2019
12.01M
Average
11.69M
Median
2021
SG&A Expense (Annual) Benchmarks
| Seelos Therapeutics Inc | 12.58M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 7.12M |